Mobile-health Network Solutions (Class A) (MNDR) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MNDR carries an RQD Score of 28 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:

• Fundamental Cash Engine (4/20): Per the RQD rating, this pillar reflects ROIC of -35% and FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to support its valuation.
• Whale 13F Flow (5/20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. A low score suggests limited institutional support in the source data.
• Insider Conviction (3/20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals.
• Macro Regime Fit (8/20): Per the RQD rating, the stock carries a Beta of 1.0 and sector sensitivity. The score is modest and does not indicate a favorable macro setup.
• Forensic Balance Sheet (8/20): Per the RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. The weak Piotroski reading is a notable forensic concern.

Taken together, the pillars point to weak fundamentals, weak institutional and insider signals, and a fragile balance sheet. Upside drivers would need to come from a turnaround in cash generation, which the current data does not show. Valuation tradeoffs are difficult to assess because P/E and EPS are not available in source data. Investors evaluating this name should weigh the forensic risk flag heavily.

Per the profile, Mobile-health Network Solutions (Class A) is a NASDAQ-listed issuer in the Technology sector, Computer Software: Prepackaged Software industry. Per the profile, its market capitalization is listed as $0.0B. Not available in source data: product lines, customer segments, or revenue model details beyond sector and industry classification.

Per the SEC financials, the company reported net losses in each listed period, with FY 2025 net income of $-3.4M and FCF of $-4.4M. Per the market data, gross margin is 16.7%, operating margin 0%, and net margin -44.3%, with ROIC of -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, a weak reading. Per the RQD rating, Debt/Equity is 0.5. Debt values are N/A for all reported periods in the financials.

Per the recent news data, several headlines reference MNDR market action on a single day: a Benzinga pre-market mention (YELLOW), a kalkine.ca report describing a 369.27% move on 28.8 times normal volume with no catalyst found (YELLOW), a Moomoo report of a 418.23% gain (GREEN, CATALYST), a Stock Titan item on a health platform set to launch in Singapore Nov. 2 (YELLOW), a Timothy Sykes piece on volatile trading (YELLOW), and a 富途牛牛 report repeating the 418.23% move (YELLOW). Risk watch: the headlines describe speculative price spikes, and one explicitly notes no catalyst was identified. Per the market data, the stock closed at $0.94, down 3.18%, on volume of 107,977. The Singapore launch is the only operational catalyst referenced. Proprietary signals: none are listed in the Butterfly graph.

• What is the source of the FY 2025 revenue decline from $14.0M to $7.6M, and is the trend expected to continue?
• What are the debt obligations behind the Debt/Equity of 0.5, given that debt values are N/A in the financials?
• Does the $3.5M cash balance cover the FY 2025 FCF burn of $-4.4M, and what is the runway?
• What drove the reported single-day price spikes described in the news, and was any catalyst confirmed?
• What is the basis for the Piotroski F-Score of 2/9 and which component metrics drive the weakness?